Forbion related stories
All articles and analysis
Gene therapy firm Gyroscope Therapeutics files to go publicGyroscope Therapeutics, a gene therapy company, has filed for an IPO.
Gyroscope Therapeutics lands $148m Series CGyroscope Therapeutics, a gene therapy company, has raised $148 million in Series C financing.
Amphista Therapeutics nabs $53m Series BAmphista Therapeutics, a provider of next-generation targeted protein degradation solutions, has secured $53 million in Series B financing.
- Forbion leads $37m round for Oxular
Oxular, a retinal therapeutics development company, has raised $37 million in funding.
- NewAmsterdam Pharma lands $196m Series A
NewAmsterdam Pharma, a clinical stage company focused on the research and development of transformative therapies for cardio-metabolic diseases, has raised $196 million in Series A funding.
- VC-backed Dyne Therapeutics goes public
Dyne Therapeutics Inc, a muscle disease company, has raised about $233 million for its IPO after pricing its over 12.2 million shares at $19 per share.
- Inversago Pharma picks up $35m in Forbion-led Series B
Montreal-based Inversago Pharma, a peripheral CB1 blockade company, has raised US$35 million in Series B funding.
- Forbion gathers $208m for new growth fund
Forbion has raised $208 million for its new growth fund.
- BGV wraps up fourth fund
BioGeneration Ventures, an early-stage venture firm focused on European biopharma, has closed its fourth fund at $119 million.
- Prilenia Therapeutics scores $62.5m Series
Prilenia Therapeutics B.V., a developer of novel treatments for neurodegenerative and neurodevelopmental disorders, has raised $62.5 million in Series A financing.